Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06623487
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-19
Brief Title:
The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer a Prospective Observationa Trial
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Neoadjuvant immunotherapy can significantly improve the pathological complete response pCR and major pathological response MPR rates in resectable stage III non-small cell lung cancer NSCLC and extend the event-free survival EFS However the current means for evaluating its efficacy are limited This study aims to utilize the convenient and non-invasive 68Ga-grazytracer PET imaging to detect the aggregation of CD8 T cells in target lesions after neoadjuvant immunotherapy for stage III NSCLC and to assess its value in efficacy monitoring providing valuable information for clinical treatment decisions
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None